Median Technologies ALMDT
EURONEXT · France · Health Services
€3.61-0.15 (-3.87%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
SOPHIA ANTIPOLIS, France, September 15, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI)-powered Software as Medical Devices (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today the signing of one of the largest projects in the Company's history for its iCRO bu
SOPHIA ANTIPOLIS, France, September 10, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer detection and diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, announced today its H2 2026 financial communication calendar.
SOPHIA ANTIPOLIS, France, September 08, 2026--Regulatory News: Median Technologies (Paris:ALMDT):
SOPHIA ANTIPOLIS, France, September 02, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), developer of eyonis®, a suite of AI-powered Software as Medical Devices (SaMD) for the early detection and diagnosis of cancers, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced that its Board of Directors has formed a Strategic Review Committee (the "SRC")
SOPHIA ANTIPOLIS, France, August 10, 2026--Regulatory News: Median Technologies (Paris:ALMDT):
Median Technologies’ agreement will expand availability of the FDA-cleared detection and diagnostic-assessment technology to U.S. radiology providers and healthcare systems The lung cancer screening paradigm change eyonis LCS is the first FDA-cleared CADe/CADx Software as a Medical Device specifically designed for lung cancer screening. SAN FRANCISCO, CA and SOPHIA ANTIPOLIS, France, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eyonis Inc., a Median Technologies company focused on applying artificial intel
The eyonis LCS Software as a Medical Device uses AI to help clinicians detect and diagnose lung cancer earlier.
SOPHIA ANTIPOLIS, France, July 30, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as Medical Devices (SaMD) for the early detection and diagnosis of cancers, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced the signing of a strategic commercial partnership with Canon Medical Systems Cor
SOPHIA ANTIPOLIS, France, July 22, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), developer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced its key financial performance for the first half of 2026 and highlighted major regulatory and commercial
SOPHIA ANTIPOLIS, France, July 15, 2026--Regulatory News: Under the liquidity contract entrusted by Median Technologies (FR0011049824, ALMDT, "Median" or "the Company") to TP ICAP (Europe), the following resources were listed in the liquidity account as of June 30, 2026:
SOPHIA ANTIPOLIS, France, July 03, 2026--Regulatory News: Median Technologies (FR0011049824, ALMDT, "Median" or the "Company"), manufacturer of eyonis®, a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced eyonis® LCS has obtained CE marking as a Class IIb medical device, under the new European Medical Dev
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.